Immunology & Rheumatology Clinical Trials

Statistical methods in immunology & rheumatology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All immunology & rheumatology trials

963 results

• anaGOIndependent statistical analysis of A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 165NCT03002974
• Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease: Complete Statistical AnalysisIndependent statistical analysis of Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00069329).Phase 1/2Results postedn = 43NCT00069329
• Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV: Complete Statistical AnalysisIndependent statistical analysis of Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 276NCT01946139
• Analytical Treatment Interruption (ATI) to Assess the Immune System’s Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study: Complete Statistical AnalysisIndependent statistical analysis of Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study: primary endpoint results,…Phase NAResults postedn = 13NCT04860323
• Anti-Tac(90 Y-HAT) to Treat Hodgkin’s Disease, Non-Hodgkin’s Lymphoma and Lymphoid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 1/2Results postedn = 87NCT00001575
• Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 1Results postedn = 3NCT00014560
• ANTIBODY-RAIndependent statistical analysis of Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase NAResults postedn = 605NCT01981473
• Antimicrobial Barrier Dressing Versus Closed-incision Negative Pressure Therapy in the Obese Primary Total Joint Arthroplasty: Complete Statistical AnalysisIndependent statistical analysis of Antimicrobial Barrier Dressing Versus Closed-incision Negative Pressure Therapy in the Obese Primary Total Joint Arthroplasty: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 230NCT03345771
• APPLEIndependent statistical analysis of Arthritis Pilot for Preserving Muscle While Losing Weight: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02239939).Phase NAResults postedn = 37NCT02239939
• ARC001Independent statistical analysis of Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 56NCT01987817
• ARICAIndependent statistical analysis of AdheRence to Inhaled Corticosteroids in Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03769519).Phase NAResults postedn = 29NCT03769519
• Arthroscopy in the Treatment of Degenerative Medial Meniscus Tear: Complete Statistical AnalysisIndependent statistical analysis of Arthroscopy in the Treatment of Degenerative Medial Meniscus Tear: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00549172).Phase NAResults postedn = 146NCT00549172
• ASCLEPIOS IAn independent statistical analysis of ASCLEPIOS I, the phase 3 double-blind comparison of ofatumumab and teriflunomide in relapsing multiple sclerosis, covering the negative binomial relapse-rate analysis, Cox models for pooled disability endpoints,…Phase 3Results postedn = 930NCT02792218
• ASCLEPIOS IIndependent statistical analysis of Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 930NCT02792218
• ASCLEPIOS IIAn independent statistical analysis of ASCLEPIOS II, the phase 3 trial of subcutaneous ofatumumab versus teriflunomide in relapsing multiple sclerosis: negative binomial annualized relapse rate, Cox models for confirmed disability, pooled analyses…Phase 3Results postedn = 955NCT02792231
• ASPIREIndependent statistical analysis of Family-Focused, Stress-Reduction Program to Improve the Health Care of Urban Children With Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 43NCT00384813
• Aspirin for Treatment of Multiple Sclerosis-Related Fatigue: Complete Statistical AnalysisIndependent statistical analysis of Aspirin for Treatment of Multiple Sclerosis-Related Fatigue: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00467584).Phase 3Results postedn = 62NCT00467584
• Assessment of Alcon’s Ocular Image Quantification System: Complete Statistical AnalysisIndependent statistical analysis of Assessment of Alcon's Ocular Image Quantification System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01282138).Phase 4Results postedn = 13NCT01282138
• Assessment of Cough Reflex in Lung Transplant Recipients: Complete Statistical AnalysisIndependent statistical analysis of Assessment of Cough Reflex in Lung Transplant Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00584077).Phase NAResults postedn = 15NCT00584077
• Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2/3Results postedn = 48NCT01997411
• Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying Anti-rheumatic Drugs or Biological Agents: Complete Statistical AnalysisIndependent statistical analysis of Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying…Phase NAResults postedn = 163NCT01783730
• ASSIST-RTIndependent statistical analysis of GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 107NCT02514772
• ASSUREIndependent statistical analysis of A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01102972).Phase 4Results postedn = 297NCT01102972
• AtazanavirIndependent statistical analysis of Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 1Results postedn = 64NCT01837719
• Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents: Complete Statistical AnalysisIndependent statistical analysis of Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 195NCT00006604
• ATLASIndependent statistical analysis of Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 302NCT03533751
• AUR0613Independent statistical analysis of Blinded, Randomized Study Evaluating Aurstat Versus Control in the Treatment of Atopic Dermatitis Associated Pruritus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 30NCT01905631
• AURIONIndependent statistical analysis of Aurinia Early Urinary Protein Reduction Predicts Response: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02949973).Phase 2Results postedn = 10NCT02949973
• Autologous and Allogeneic Transplant for Relapsed Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Autologous and Allogeneic Transplant for Relapsed Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00802113).Phase 1/2Results postedn = 30NCT00802113
• Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin’s Lymphoma (BMT CTN 0202): Complete Statistical AnalysisIndependent statistical analysis of Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2/3Results postedn = 30NCT00096460
• Autologous Polyclonal Tregs for Lupus: Complete Statistical AnalysisIndependent statistical analysis of Autologous Polyclonal Tregs for Lupus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02428309).Phase 1Results postedn = 1NCT02428309
• Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 41NCT01849783
• Avenir Müller Hip Stem Post Market Surveillance Study: Complete Statistical AnalysisIndependent statistical analysis of Avenir Müller Hip Stem Post Market Surveillance Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04079127).Phase NAResults postedn = 150NCT04079127
• AwareIndependent statistical analysis of HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 5,012NCT01154296
• AZI001Independent statistical analysis of Azithromycin in Bronchiolitis Obliterans Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01009619).Phase 4Results postedn = 83NCT01009619
• AZMATICS: AZithroMycin/Asthma Trial In Community Settings: Complete Statistical AnalysisIndependent statistical analysis of AZMATICS: AZithroMycin/Asthma Trial In Community Settings: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00266851).Phase 3Results postedn = 97NCT00266851
• Balance Training for People With Multiple Sclerosis Using Nintendo Wii Fit: Complete Statistical AnalysisIndependent statistical analysis of Balance Training for People With Multiple Sclerosis Using Nintendo Wii Fit: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 84NCT01299025
• BALLAD+Independent statistical analysis of A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid: primary endpoint results, effect estimate with…Phase 3Results postedn = 64NCT05681481
• BEe-HIVeIndependent statistical analysis of B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 638NCT04193189
• BEGINIndependent statistical analysis of A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 105NCT04004429
• BEGIN™Independent statistical analysis of Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01079234).Phase 3Results postedn = 493NCT01079234
• BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115: Complete Statistical AnalysisIndependent statistical analysis of BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115: primary endpoint…Phase 3Results postedn = 142NCT01597622
• Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04676360).Phase 2Results postedn = 10NCT04676360
• Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients: Complete Statistical AnalysisIndependent statistical analysis of Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02152345).Phase 4Results postedn = 57NCT02152345
• Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 21NCT03311126
• Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin’s Lymphoma(NHL): Complete Statistical AnalysisIndependent statistical analysis of Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00426855).Phase 1/2Results postedn = 12NCT00426855
• Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00705250).Phase 2Results postedn = 36NCT00705250
• Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 45NCT00891839
• Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 24NCT02224729
• Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL): Complete Statistical AnalysisIndependent statistical analysis of Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 27NCT02433795

← All therapeutic areas